TANAKA Contributes to Global Vascular

TANAKA Kikinzoku Kogyo K.K. has provided an equity contribution to Global Vascular Co. Ltd. Details of the transaction were not released, though TANAKA said the monetary infusion represents a direct investment into a company by DMC (Diamond Medino Capital) 1st  Fund Investment Limited Partnership—a medical venture capital fund that TANAKA formally committed to supporting in November 2022.

Established in December 2022, Global Vascular is a medical venture company developing a stent delivery system to treat lower limb ischemia. The stent’s design and high-performance surface modification technology was pioneered by Terumitsu Hasebe, a professor at the Tokai University School of Medicine, and renowned researcher in endovascular treatment device development; and Kenta Bito and Shunto Maegawa, who have conducted biomaterials research since 2013 as part of the Hasebe Research Group. The product could provide physicians with a new treatment method for below-the-knee atherosclerosis and help broaden TANAKA’s medtech sector footprint.  

Tokyo-based Global Vascular boasts 282 million yen in capital. 

Since its foundation in 1885, TANAKA Precious Metals has built a portfolio of products to support a diversified range of business uses focused on precious metals. Over the course of many years, TANAKA has not only manufactured and sold precious metal products for industry but also provided precious metals in such forms as jewelry and assets. As precious metals specialists, all Group companies in Japan and worldwide collaborate and cooperate on manufacturing, sales, and technology development to offer a full range of products and services. With 5,355 employees, the group’s consolidated net sales for the fiscal year ending March 31, 2023, was 680 billion yen.